CME / ABIM MOC / CE

Mesothelioma: Updates in Current and Emerging Therapies

Authors: Charlotte Warren
CME / ABIM MOC / CE Released: 5/8/2023
Valid for credit through: 5/8/2024, 11:59 PM EST

Credits Available

Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.25 ABIM MOC points

Nurses - 0.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with mesothelioma.

The goal of this activity is for learners to be better able to evaluate the treatment options for mesothelioma.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data for the treatment of mesothelioma
Demonstrate greater confidence in their ability to
- Recognize treatment-related adverse events (TRAEs) associated with systemic therapies for malignant pleural mesothelioma

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Charlotte Warren

Senior Director, Content Development, Medscape, LLC

Disclosures

Charlotte Warren has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Contact This Provider

For Nurses

Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-163-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

processing....

References

Janes SM, et al. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385:1207-1218.
NCCN guidelines. Mesothelioma: pleural. Version 1.2023. Accessed April 18, 2023. https://www.nccn.org/professionals/physician_gls/pdf/meso_pleural.pdf
Zalcman G, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405-1414. Published correction appears in Lancet. 2016 Apr 2;387(10026):e24.
Pinto C, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021;22:1438-1447.
Douma LAH, et al. PEMbrolizumab plus lenvatinib in second and third line malignant pleural MEsotheLiomA patients: a single arm phase II study (PEMMELA). J Thorac Oncol. 2022;17:S13. Abstract OA04.
Peters S, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33:488-499.
Zalcman G, et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743. Ann Oncol. 2022;33(suppl_7):S808-S869. Abstract LBA71.
Fennell DA, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22:1530-1540.
Fennell DA, et al. A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma. J Clin Oncol. 2021;39(suppl 15): Abstract 8507.
Nowak AK, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21:1213-1223.
ClinicalTrials.gov. DuRvalumab with chEmotherapy as first line treAtment in advanced pleural mesothelioma (DREAM3R). Accessed April 17, 2023. https://clinicaltrials.gov/ct2/show/NCT04334759
ClinicalTrials.gov. BEAT-meso: bevacizumab and atezolizumab in malignant pleural mesothelioma (BEAT-meso). Accessed April 17, 2023. https://clinicaltrials.gov/ct2/show/NCT03762018
Szlosarek PW, et al. Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma. AACR Annual Meeting 2023, April 14-19, 2023, Orlando, Florida. Abstract CT007.
Yap T, et al. First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. AACR Annual Meeting 2023, April 14-19, 2023, Orlando, Florida. Abstract CT006.
ClinicalTrials.gov. Oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors. Accessed April 17, 2023. https://clinicaltrials.gov/ct2/show/NCT05228015
ClinicalTrials.gov. Study of HPN536 in patients with advanced cancers associated with mesothelin expression. Accessed April 17, 2023. https://clinicaltrials.gov/ct2/show/NCT03872206
ClinicalTrials.gov. Phase 1/2 Study of MRTX1719 in solid tumors with MTAP deletion. April 17, 2023. https://clinicaltrials.gov/ct2/show/NCT05245500
ClinicalTrials.gov. Safety and tolerability of TNG908 in patients with MTAP-deleted solid tumors. Accessed April 17, 2023. https://clinicaltrials.gov/ct2/show/NCT05275478
ClinicalTrials.gov. Study of IDE397 in participants with solid tumors harboring MTAP deletion. Accessed April 17, 2023. https://clinicaltrials.gov/ct2/show/NCT04794699

« Return to: Mesothelioma: Updates in Current and Emerging Therapies

CME / ABIM MOC / CE Information

Print
Like Tweet

Faculty and Disclosures

Faculty

Charlotte Warren

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

CME / ABIM MOC / CE

Mesothelioma: Updates in Current and Emerging Therapies

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Charlotte Warren

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Mesothelioma: Updates in Current and Emerging Therapies

References